preferential staining of mitotic cells following indirect The MPM-2 monoclonal antibody recognizes a dis-immunofluorescence localization [1] . A dramatic intinctive group of proteins that are associated with crease in the levels of MPM-2 reactive proteins is obstructural components of the mitotic apparatus. These served during the G 2 /M transition in all eukaryotic speproteins become phosphorylated and MPM-2 reactive cies examined. Some of the MPM-2 antigens are presduring M-phase and appear to be required for both ent on important components of the mitotic apparatus, the onset and completion of M-phase. Based upon the including chromosomes, kinetochores, centrosomes, analysis of reported MPM-2 reactive sequences, we and midbodies [2, 3] . Among the identified cell cyclehave developed a model for the essential elements that dependent MPM-2 reactive proteins are microtubule- immunostaining of mitotic cells. These results indi-cycle-regulated MPM-2 reactive proteins. It was also cated that the topoisomerase peptide contained all of hypothesized that this kinase, together with these the essential elements of the MPM-2 epitope. By substi-MPM-2 reactive proteins, constitute an integral part of tuting selected amino acids with alanine, we were able the M-phase regulatory mechanism. Despite signifito examine the contribution of different amino acids cant effort, the MPM-2 epitope and the putative MPMto the binding between the MPM-2 antibody and the 2 kinase have not been clearly identified.
INTRODUCTION
sible that only a subset of MPM-2 reactive epitopes, those dependent upon the activity of particular ki-MPM-2 is a monoclonal antibody that was raised nase(s) in the mitotic cell extract under the selected against mitotic HeLa cells and is characterized by its experimental conditions used, were identified by this approach. 1 To whom correspondence and reprint requests should be adAnother MPM-2 reactive site has been identified by dressed at Department of Cell Biology, Neurobiology, and Anatomy, Taagepera et al. [7] by its comigration with an MPM-2 reactive band in extracts of Xenopus eggs. This MPM-2 reactive site was tope. Further, a proline residue adjacent to the phosphorylated serine or threonine on the C-terminal side shown to contain a phosphorylated threonine residue in the sequence TEY, the regulatory sequence on p42 mapk is not required for antibody recognition of the epitope. Our findings provide the basis for a more complete phosphorylated by MAP kinase kinase [7] . These results suggest that the proline residue C-terminal to analysis of the MPM-2 epitope and may be useful in identifying potential MPM-2 target sequences. In addithe phosphorylated residues is not required for MPM-2 recognition. The tyrosine residue in this sequence tion, our results provide a model for the MPM-2 epitope that includes both proline-directed as well as prolineof p42 mapk is also phosphorylated in vivo and limited mutagenesis of this site showed that the Y r F muta-independent phosphorylation sites. tion maintained MPM-2 reactivity, while the Y r E mutation showed weakened reactivity. Thus, it was
MATERIALS AND METHODS
demonstrated that neither the phosphorylation of the tyrosine residue nor the negative charge at that posiMaterials. Peptides P1 and P2 were synthesized by AnaSpec Inc.
tion were required for MPM-2 reactivity. In addition, (San Jose, CA). Peptides P3, P4, and P5 were synthesized by Princeton BioMolecules Corp. (Columbus, OH). The HPLC purity of the downstream F/Y appeared to promote MPM-2 bindthese peptides was greater than 95%. MPM-2 mouse monoclonal ing while E hindered binding [7] , suggesting the imporantibody was a generous gift from Dr. Potu Rao (Department of tance of the aromatic residue. Since this epitope was Chemotherapy Research, The University of Texas M. D. Anderson identified on a protein whose phosphorylation is not Hospital and Tumor Institute, Houston, TX) or purchased from Uptypically associated with mitosis, it could be argued state Biotechnology Inc. (Lake Placid, NY). Peroxidase-conjugated goat anti-mouse antibody was purchased from Kirkegaard and Perry that this proline-independent site is not reflective of the Laboratories (Gaithersburg, MD). Keyhole limpet hemocyanin was majority of the MPM-2 reactive epitopes found during obtained from CalBiochem (LaJolla, CA), and m-maleimidobenzoylmitosis that might contain a proline-directed phosphor-N-hydroxysuccinimide ester (MBS) from Pierce (Rockford, IL). Preylation site.
pared PD-10 Sephadex columns were obtained from Pharmacia (UpBased solely upon these two previous reports [7, 13] , psala, Sweden). Fetal bovine serum was obtained from Intergen Co.
(Purchase, NY), and all other tissue culture components from Gibco it is difficult to identify common elements that would BRL Products (Gaithersburg, MD). Cy3-conjugated donkey antibe required to define an epitope recognized by the same mouse secondary antibody was obtained from Jackson ImmunoRemonoclonal antibody. However, upon careful analysis search Laboratories (West Grove, Pennsylvania). Mitotic HeLa of the reported epitope sites certain common features MAP4 was kindly provided by Yunhi Choi (this lab) and was purified are detected. In order to further define the MPM-2 epi-essentially as described by Vallee and Collins [15] . tope, we have designed a series of synthetic peptides Cell culture. The HeLa human cervical carcinoma, Chinese hamster ovary (CHO), and LLC-PK pig kidney cell lines were maintained based upon a potential MPM-2 reactive site associated in DMEM, Ham's F-10, and Medium 199, respectively. The media with human topoisomerase II [14] .
were supplemented with 10% fetal bovine serum (FBS) and gentaWe demonstrate here that the phosphorylated form mycin (50 mg/ml) with the exception of the Medium 199, which conof a 13 amino acid synthetic peptide corresponding to tained 3% FBS and gentamycin. Cells were maintained as monolayer cultures at 37ЊC in a humidified atmosphere containing 5% CO 2 .
the potential MPM-2 site in topoisomerase II is indeed MPM-2 reactive, while the corresponding dephosphoConjugating peptides to KLH. Synthetic peptides were conjugated to keyhole limpet hemocyanin (KLH) using a modification of peptide is not recognized by the antibody. We have also the procedure described by Coligan et al. [16] . Briefly, KLH (5 mg) shown that this synthetic phosphopeptide is sufficient was dissolved in 0.5 ml Buffer A (0.01 M phosphate buffer, 0.9 M to compete for antibody binding to a native mitotic NaCl, 0.01 M EDTA, pH 7.0) and dialyzed against Buffer A overnight MPM-2 antigen, MAP4, blocks MPM-2 recognition of at 4ЊC. MBS was dissolved in dimethylformamide (15 mg/ml) immediately before use, and 70 ml was added to the dialyzed KLH. The proteins in mitotic cell lysates examined by immumixture was gently stirred for 30 min at room temperature, at which noblot, and prevents MPM-2 antibody localization to time it was applied to a PD-10 column and eluted with Buffer B cellular structures by indirect immunofluorescence. We (0.05 M phosphate buffer, 0.9 M NaCl, 0.01 EDTA, pH 6.0). The first also designed and synthesized three more phosphopep-peak eluted (KLH-MBS) was pooled and mixed with 5 mg of synthetic tides each containing a single amino acid change from peptide that was dissolved in 1 ml of Buffer B. The pH was adjusted to 7.3 and the sample was gently stirred for 3 h at room temperature. the native sequence. These altered peptides allowed us
The reaction mixture was dialyzed twice against distilled water at to examine the contribution of aromatic residues both 4ЊC, lyophilized, and stored at 020ЊC.
N-and C-terminal to the phosphothreonine residue on
Immunoblot blot and competition experiments. A Bio-Dot apparaantibody recognition. We show that the alteration of tus (Bio-Rad Laboratory, Hercules, CA) was used for applying samthe aromatic residue to the N-terminal side nearly ples to nitrocellulose paper. Samples were first diluted to a total eliminated MPM-2 reactivity. Changing the C-terminal volume of 50 ml in TBS (154 mM NaCl, 10 mM Tris-Base, pH 7.4) and added to each well. The samples were applied to the nitrocelluaromatic residue to alanine also reduced antibody bindlose under vacuum, and the wells were then washed several times ing, but the reduction in binding was not to the same with a large volume of TBS. The nitrocellulose was removed from extent as the alteration of the N-terminal aromatic res-the Bio-Dot apparatus, rinsed in TBS, and then blocked in 10% heatidue. These results strongly support a role for these inactivated horse serum in TBS for 1 h. Dot blots were incubated with various dilutions of the MPM-2 antibody for 1 h, washed in flanking aromatic residues in defining the MPM-2 epi- [7] and corresponds to amino acids 164-176 of human p42mapk. for 30 min prior to incubation in primary MPM-2 antibody. The The remaining sequences were reported by Westendorf et al. and MPM-2 antibody (1:8000) was preincubated for 1 h at room temperarepresent the most commonly identified MPM-2 reactive peptides in ture with various concentrations of the synthetic peptides prior to this report [13] . The sequences were aligned along the position of a incubation with the coverslips for 1 h at 37ЊC. After rinsing the potential phosphorylated residue, and multiple alignments are possiprimary antibody off in three changes of PBS, the secondary Cy3-ble with some peptides as indicated. The presence of an aromatic conjugated donkey anti-mouse antibody (1:250) was applied for 30 amino acid on the N-terminal side of the potential phosphorylation min at 37ЊC. DNA was stained with DAPI (0.2 mg/ml) diluted in PBS site is highlighted in bold type. Peptides 2 and 3 represent synthetic for 10 min during the second of three PBS rinses of the secondary peptides generated by Westendorf et al. [13] . Interestingly, peptide antibody. Coverslips were mounted in mowiol containing 1 mg/ml of 2 was reported to have strong affinity for MPM-2, while peptide 3 p-phenylenediamine and examined with epifluorescence using a was reported to have weak affinity for MPM-2. Peptide 3 lacks an Zeiss Axioskop and a Zeiss 1001 Plan Neofluar 1.3 NA objective. N-terminal aromatic residue; however, the N-terminal aromatic resiPhotomicrographs were recorded using a Zeiss MC-100 camera sys-due is present on the related peptide 4, which was reported to bind tem and Kodak T-MAX 400 film.
the MPM-2 antibody. Image analysis. Images of the developed dot blots were captured using an MTI-CCD72 camera equipped with a Nikon lens (AF Micro Nikkor 60 mm 1:2.8 D). All of the dot blots quantified within each aromatic residue was located at the 02 position. Many figure of the text were captured in the same image to insure that the acquisition of data was internally consistent. The captured imof the MPM-2 reactive sequences also contained either ages were analyzed using Optimas Image Analysis Software (Opti-an aromatic amino acid or one or more positively mas Corp.). The integrated optical densities were extracted from the charged amino acids (most commonly R, K) on the Cimages and exported to Microsoft Excel for Windows (Microsoft terminal side of the phosphorylated T/S residue. ThreoCorp.) and used to plot the corresponding charts.
nine was clearly the most frequent amino acid located at the phosphorylation site. In addition, while the ma-RESULTS jority of the MPM-2 reactive peptides contained a proline residue adjacent to the phosphorylated residue on The MPM-2 Antibody Recognizes a Phosphopeptide the C-terminal side, the presence of a proline was not Conserved in Human DNA Topoisomerase required at this position since the MPM-2 epitope site IIa and IIb reported for p42 mapk lacked this proline residue [7] . Based upon our analysis, we developed a hypothetiWe examined the sequences of the previously reported MPM-2 reactive peptides and protein epitopes cal model that would define critical components of the MPM-2 epitope. Our model would predict that maximal [7, 13] , in an effort to identify similarities in their structures that may be related to antibody recognition (Ta-MPM-2 antibody binding would be achieved if (1) the phosphorylated residue was a threonine, (2) the phosble 1). The presence or absence of structurally related groups of amino acids were determined for each residue phorylated amino acid was located near an aromatic amino acid to its N-terminal side, and (3) either an of the MPM-2 reactive peptides on both the N-terminal and C-terminal sides of the phosphorylated amino acid. aromatic or positively charged amino acid was located to its C-terminal side. A group of amino acids was considered irrelevant to the MPM-2 epitope if none of the amino acids within
In order to test the validity of this model, we designed a series of synthetic peptides that could be used to the group appeared consistently. As a result of this analysis, we found that 90% of the sequences examined examine the potential contribution of specific amino acids to the MPM-2 epitope. We first needed to estabcontained an aromatic amino acid (most commonly F or W and to a lesser extent Y) on the N-terminal side of lish that a small synthetic peptide obtained from a defined MPM-2 reactive protein was capable of binding the phosphorylated T/S residue. Most frequently, this to the MPM-2 antibody. Further, this phosphopeptide needed to have an affinity for the MPM-2 antibody that was comparable to a native in vivo MPM-2 antigen. It has been reported that topoisomerase IIa and IIb were MPM-2 reactive in a cell cycle-dependent fashion [6] . Thus, we prepared a synthetic peptide containing 13 amino acids based upon a putative MPM-2 epitope site in topoisomerase II [14] . An amide-cystine residue was added to the C-terminal end of the peptide to allow for conjugation to carrier protein (Table 2, P1). The phosphorylated form of this peptide was also synthesized (Table 2, P2 ). This phosphopeptide met the three characteristics we proposed for an MPM-2 epitope, it contained a phosphothreonine residue, an aromatic residue at the 02 position relative to the phosphothreonine, and an aromatic residue at the /2 position. These peptides were individually conjugated to KLH as described under Materials and Methods and tested for their ability to react with the MPM-2 antibody. While an unconjugated KLH control along with the P1-KLH conjugate showed no affinity for the MPM-2 antibody (see below, Fig. 4A , KLH and P1), the P2-KLH conjugate exhibited strong affinity for the MPM-2 antibody similar to that for a human MPM-2 reactive protein, mitotic HeLa cell MAP4 (Fig. 1A) . We observed a titration of the MPM-2 antibody against a fixed amount of the P2-KLH conjugate (Fig. 1C) , similar to that observed using mitotic MAP4 (Fig. 1B) .
There was a slight possibility that certain amino acid/motifs on KLH may contribute to the MPM-2 reactivity of the peptide after conjugation. In order to obtain an unambiguous result, we tested the affinity of the unconjugated peptides for the MPM-2 antibody. Varying amounts of each peptide were preincubated with a constant amount of the MPM-2 antibody. This peptide- Fig. 2A, P2 ). This inhibition was grated Optical Density) against the antibody concentrations used, based upon the data from A.
TABLE 2
clearly dependent upon the amount of peptide preincuPeptide constructs bated with the MPM-2 antibody (Fig. 2B) . On the other hand, the nonphosphorylated P1 peptide failed to ex- 2 antibody and MAP4 ( Fig. 2A, P1 (Fig. 4) . As can be seen in the immunoblots of both cell types, preincubation of the MPM-2 antibody with increasing concentrations of P1 (up to 100 mg/ml) had no effect on the recognition of mitotic phosphoproteins in these samples. However, preincubation of the MPM-2 antibody with the phosphorylated topoisomerase II peptide (P2) inhibited the binding of MPM-2 to all of the mitotic phosphoproteins. Similar results were obtained with populations of S phase cells synchronized using hydroxyurea and cells in logarithmic growth (data not presented).
The immunofluorescence localization of the MPM-2 antibody in LLC-PK cells was also inhibited by preincubation with the P2 synthetic peptide regardless of cell cycle stage (Fig. 5) . In control cells, weak MPM-2 antibody staining of patches in the nuclei of interphase cells was observed, while more intense nuclear staining for the binding of the antibody to a mitotic protein known to be MPM-2 reactive in vivo. This suggested that the P2 phosphopeptide, derived from human topoisomerase II, contains all the elements of the MPM-2 epitope necessary for MPM-2 binding.
Recognition of Mitotic Phosphoepitopes by the MPM-2 Antibody Is Blocked by Preincubation with the Synthetic Topoisomerase II Phosphopeptide But Not by the Corresponding Dephosphopeptide
It was possible that the P2 phosphopeptide represented only a subset of the mitotic phosphoepitopes recognized by the MPM-2 antibody since it lacked the proline residue C-terminal to the phosphorylated amino acid that is common both to most previously identified MPM-2 reactive peptides [7] , as well as con-
FIG. 3. Competition of synthetic peptides for MPM-2 antibody
sensus phosphorylation sites for kinases that are binding to the P2-KLH conjugate. (A) Peptides P1 or P2 were used known to be active at mitosis, such as the cyclin-depen-to compete for binding of MPM-2 antibody against P2-KLH conjugate dent kinases. To ensure that the topoisomerase II phos-blotted onto nitrocellulose paper. P2-KLH conjugate (1.25 mg) was applied to each dot. Different amounts (mg) of the P1 or P2 synthetic phopeptide was indeed representative of all MPM-2 repeptides were added to 3 ml of MPM-2 antibody solution diluted to active epitopes, we determined whether preincubation 1:20,000 and preincubated for 1 h prior to application to the dot-blot. of the MPM-2 antibody with peptide in either the de-(B) The amount of bound MPM-2 antibody was determined using phosphorylated (P1) or phosphorylated form (P2) would image analysis software and plotted against the amounts of synthetic peptides P1 (ᮀ) or P2 () preincubated with the MPM-2 antibody. inhibit antibody reactivity. eliminated and the centrosomal staining intensity was reduced. At concentrations of 100 mg/ml, preincubation with P2 totally abolished MPM-2 staining, while similar levels of P1 had no effect on MPM-2 staining patterns.
These results strongly indicate that the synthetic phosphopeptide P2 that is derived from the sequence of topoisomerase II represents a typical MPM-2 epitope in that this peptide can compete for the binding of the MPM-2 antibody with all mitotic phosphoproteins recognized by the antibody.
Critical Components of the MPM-2 Phosphoepitope Include Aromatic Amino Acids Located Both to the N-and C-Terminal of the Phosphorylated Residue
Having shown that the P2 phosphopeptide derived from topoisomerase II was indeed sufficient to serve as an MPM-2 epitope, we further examined the characteristics of this epitope by changing selected amino acids to alanine (Table 2 , peptides P3, P4, and P5). These residues were selected to examine the importance of the aromatic amino acids on either side of the phos -FIG. 4 . Competition of synthetic peptides for MPM-2 antibody phothreonine residue. Each of these phosphopeptides binding to immunoblots of mitotic cell lysates. (A) CHO mitotic cell were also conjugated to KLH and tested on dot-blots lysates were separated by SDS-PAGE on a 7.5% acrylamide gel, for their MPM-2 reactivity as described above. We comtransferred to nitrocellulose, and probed with MPM-2 antibody that pared the staining of the KLH conjugates containing had been preincubated with dephosphorylated peptide P1 (lanes 1, 2, and 3) or phosphorylated peptide (lanes 4, 5, and 6) for 1 h at the modified peptides with the original P2-KLH conjuroom temperature. Increasing peptide concentrations of 0.1 mg/ml gate (Fig. 7A) . Changing from N at the /1 position to (lanes 1 and 4), 1.0 mg/ml (lanes 2 and 5), or 10.0 mg/ml (lanes 3 and A did not generate any observable difference in the 6) were used. (B) Immunoblot of HeLa mitotic cell lysates separated affinity of this peptide conjugate for the MPM-2 antiand transferred to nitrocellulose as in A. The MPM-2 antibody was body (Fig. 7, P3 ). This result was not unexpected, since preincubated with peptide P1 (lanes 1, 2, 3, and 4) or peptide P2
(lanes 5, 6, 7, and 8). Increasing peptide concentrations of 0.1 mg/ml this modification did not affect either of the flanking (lanes 1 and 4), 1.0 mg/ml (lanes 2 and 5), 10.0 mg/ml (lanes 3 and aromatic residues. In addition, the minimal effect of 6) , and 100.0 mg/ml (lanes 4 and 8) were used. In each cell type the this alteration further indicated that proline was not dephosphorylated peptide P1 had no effect on the binding of MPMrequired at the /1 position in the MPM-2 epitope. A at the 02 position greatly reduced this peptide's ability to bind to MPM-2 antibody. Binding of MPM-2 antibody to the P4-KLH conjugate was observed only at extremely high substrate amounts, and also higher anobserved in metaphase cells (Fig. 5) . Preincubation of the MPM-2 antibody with the P2 phosphopeptide elimi-tibody concentrations (Fig. 7B, P4) . The P4-KLH conjugate was not detected using lower antibody concentranated the specific localization of the MPM-2 antibody at every stage of the cell cycle (Fig. 5) . The staining of tions that still reacted with the P2-KLH conjugate (Fig.  7A, P4) . Interestingly, changing the aromatic acid at metaphase cells with the MPM-2 antibody preincubated with various amounts of the P1 or P2 peptide is the /2 position from F to A produced little difference in the ability of this peptide conjugate, P5-KLH, to represented in Fig. 6 . The inhibitory effect on MPM-2 staining was specific for the P2 phosphopeptide, as pre-act with the MPM-2 antibody (Fig. 7A, 10 and 2 mg) .
Decreased staining was only observed when the incubation with the P1 dephosphopeptide had no effect on MPM-2 localization (Fig. 6, and data not presented) . amount of the P5-KLH conjugate present on the dot blot was greatly reduced (Fig. 7A, 0.4 mg) . In addition, the inhibition of MPM-2 staining was also dependent upon the concentration of P2 peptide used These results showed that the aromatic amino acid on the N-terminal side of the phosphothreonine is critiduring the preincubation with the antibody (Fig. 6). A decrease in the level of MPM-2 antibody staining was cal for the binding of MPM-2 antibody. However, we had also proposed an important role in the binding of apparent at P2 concentrations as low as 1 mg/ml, where the cytoplasmic staining of mitotic cells was nearly MPM-2 for the aromatic amino acid at the /2 position,
FIG. 5.
Inhibition of MPM-2 immunofluorescence staining by preincubation with the phosphopeptide P2. LLC-PK cells were doublelabeled by indirect immunofluorescence with the MPM-2 antibody at a dilution of 1:16,000 (A, C, E, G, I, and K) and DAPI to stain cellular DNA (B, D, F, H, J, and L). Control MPM-2 staining showed weak staining of patches within the nucleus of interphase cells (A), and intense nuclear staining of the nucleus in prophase cells (E). The two centrosomes were also stained by MPM-2 in the prophase cell (E, arrowheads). Both the cytoplasm and the mitotic spindle were intensely stained in control metaphase cells (I). Following preincubation with 10 mg/ml of the phosphorylated peptide P2, MPM-2 staining of the interphase nucleus was abolished (C). Specific immunolocalization of the MPM-2 antibody was also nearly eliminated in both prophase and metaphase cells following preincubation with P2 (G and K, respectively). Some weak staining was still observed over the metaphase spindle by the preincubated MPM-2 antibody. Similar reduction in the level of MPM-2 staining was observed in cells regardless of cell cycle stage following preincubation with the P2 peptide (data not presented). Bar, 10 mm.
but the dot-blots suggested that this amino acid has sible to use the peptide conjugate alone to quantitatively assess the level of MPM-2 reactivity. In order to only a limited effect on the antibody-antigen binding.
Since the conjugation efficiency of each synthetic obtain a more precise indication as to the extent with which these amino acids might contribute to the MPMpeptide with KLH may not be identical, it was not pos- or peptide-KLH conjugates (P1, P2, P3, P4, and P5) were applied to the nitrocellulose paper and tested for their MPM-2 binding ability at different antibody dilutions (A, 1:10,000; B, 1:1,000). Antibody binding was compared between the control topoisomerase peptide P1 and P2, and these modified phosphopeptides P3, P4, and P5 (see Table 2 ).
2 epitope, we again examined each peptide using the DISCUSSION competition experiments. As expected, preincubation with peptide P3 inhibited the ability of the MPM-2 antiIn this report, we have shown that a synthetic phosphopeptide composed of 14 amino acids has the capacbody to bind to the P2-KLH conjugate (Fig. 8 ). In contrast, peptide P4 did not inhibit binding of the MPM-ity to serve as an epitope for the MPM-2 monoclonal antibody. This phosphopeptide can compete against 2 antibody, except at relatively high phosphopeptide concentrations (Fig. 8) . Both the P3 and P4 competition both native and synthetic MPM-2 antigens for the binding of the MPM-2 antibody. This peptide was derived experiments were consistent with the previous dot blot results (Fig. 7) , indicating that the weak reaction of from the sequence of topoisomerase II, which has been reported to be an MPM-2 reactive protein that is phosthe MPM-2 antibody with the P4-KLH conjugate was not simply due to differences in the level of peptide phorylated in a cell cycle-dependent fashion [6] . We have demonstrated the importance of an aromatic conjugation.
In contrast to the dot blot results, which demon-amino acid on the N-terminal side of the phosphothreonine for the antibody-antigen interaction. Our data on strated a similar ability of the P5-KLH conjugate to bind the MPM-2 antibody (Fig. 7) , the P5 phospho-the /2 position indicates that an aromatic amino acid at the C-terminal side will also enhance the binding peptide showed an intermediate ability to compete against the P2-KLH conjugate (Fig. 8) . Thus the com-between the MPM-2 antibody and antigen, confirming results reported for the MPM-2 epitope of p42 mapk [7] . petition experiment gave a more precise quantitative measurement of the differences between each of the In contrast to the previously reported requirement for a proline at the /1 position of the MPM-2 epitope synthetic peptides and their interaction with the MPM-2 antibody than that which could be achieved [13] , we have shown that proline is not required at this position for antibody recognition. The identificausing the dot blots.
In summary, our results indicate that in addition to tion and characterization of proline-directed MPM-2 reactive epitopes reported by Westendorf et al. [13] , the phosphorylated threonine, the aromatic residue at the 02 position was essential for MPM-2 recognition required that the peptide substrates were phosphorylated with kinases present in a mitotic cell extract of the P2 phosphopeptide. The aromatic residue at the /2 position was also important, but contributes less to prior to reaction with the MPM-2 antibody. This was necessary, since posttranslational modifications such the antibody binding than that at the 02 position. A diagram that depicts our model of the MPM-2 epitope, as phosphorylation are not carried out in the expression systems which were utilized [13] . Thus, these which is based upon the results obtained in this study, is presented in Fig. 9 .
MPM-2 reactive phosphopeptides were preselected by   FIG. 6 . Inhibition of the MPM-2 mitotic immunostaining is dependent upon preincubation of the antibody with phosphorylated peptide. Micrographs of double-labeled metaphase LLC-PK cells are presented. Preincubation of the MPM-2 antibody (1:16,000 dilution) with increasing concentrations of dephosphorylated peptide P1 had no effect on the staining of mitotic structures, including the mitotic cytoplasm, spindle poles, kinetochores, or kinetochore fibers. (A, C, E, and G). The corresponding DAPI staining patterns are also shown (B, D, F, and H). Preincubation of the MPM-2 antibody with increasing concentrations of the phosphorylated peptide P2 inhibited the MPM-2 staining of all mitotic structures (I, K, M, and O). Corresponding DAPI staining demonstrates that all cells were in metaphase (J, L, N, and P). Peptide concentrations used during the preincubation with the MPM-2 antibody were 0.1 mg/ml (A and I), 1.0 mg/ml (C and K), 10.0 mg/ml (E and M), and 100.0 mg/ml (G and O). Concentrations of the P2 peptide as low as 1.0 mg/ml were able to significantly reduce the level of MPM-2 staining of the mitotic cells, whereas 100.0 mg/ml completely abolished MPM-2 staining. Bar, 10 mm. their ability to be phosphorylated in vitro, and it is possible that other MPM-2 reactive substrates were not detected due to the conditions used to phosphorylate the peptide samples. Our results suggest that the /1 position has little or no influence on the recognition of the phosphoepitope by the MPM-2 antibody. Similarly, a proline was not present in the /1 position of the MPM-2 epitope reported on p42 mapk [7] . Therefore, while mitosis-specific substrates for the MPM-2 antibody may contain a proline residue at the /1 position, some of the MPM-2 epitope sites may contain prolinedirected sites, but they need not be restricted to proline-directed sites.
Based upon the analysis of the MPM-2 reactive se-nine. Thus, an MPM-2 phosphoepitope will exhibit maximal antibody affinity when both the flanking Nquences reported here, and those previously described [7, 13] , we propose a model for the interaction between and C-terminal elements are present. We speculate that native MPM-2 reactive proteins will contain these the MPM-2 antibody and the MPM-2 epitope (Fig. 9 ). Most importantly, the epitope requires a phosphory-epitope determinants. All of the factors that define the MPM-2 epitope have not been fully delineated, howlated amino acid, preferably phosphothreonine, although phosphoserine appears to be able to substitute. ever, and we would expect that other elements having either positive and negative effects remain to be deHowever, the phosphothreonine itself is not sufficient for the binding of antibody. An aromatic amino acid on fined. For example, a proline residue located at the /1 position, while not required for antibody binding, may the N-terminal side of the phosphothreonine appears to have a major positive influence on forming a stable enhance antibody binding.
Several protein kinases have been implicated in the complex between the MPM-2 antibody and the antigen. The stability of the complex will be further enhanced phosphorylation of MPM-2 epitope, including MEK [7] , MAPK [17] , and cdc2 [13] . In addition, a novel and as if there is an aromatic amino acid or positively charged amino acid on the C-terminal side of the phosphothreo-yet unidentified kinase that phosphorylates the MPM-2 epitope site of topoisomerase II corresponding to peptide P2, as defined here, may also exist. Although it is possible that a single MPM-2 kinase phosphorylates most MPM-2 sites in vivo, our data on the structural requirements of the MPM-2 epitope, as well as the multiple MPM-2 kinases that have been characterized to date, indicates that the MPM-2 epitope may coexist or partially overlap with a number of kinase consensus sequences. Each of these different kinases may be responsible for the phosphorylation of one or more MPM-2 reactive proteins. It is likely that only some of the substrate proteins for these kinases contain all of the essential elements of the MPM-2 epitope, and only these selected substrates will become MPM-2 reactive following phosphorylation. For example, this would explain how the cdc2 kinase might restore binding to the P2-KLH conjugate. Synthetic phosphopeptides P3, P4, MPM-2 reactivity on some proteins, whereas most cdc2 or P5 were used to compete for binding of the MPM-2 antibody phosphorylation sites would not be recognized by the against the P2-KLH conjugate blotted onto nitrocellulose paper. The MPM-2 antibody.
bound MPM-2 antibody was visualized, and the density of the reaction product was determined by image analysis and plotted against Several proteins recognized by MPM-2 have been the amounts of the P3 (), P4 (ᮀ), or P5 (᭝) synthetic peptides shown to be present during interphase, but they only preincubated with the MPM-2 antibody. P2-KLH conjugate (1.25 mg) become MPM-2 reactive during M-phase [5, 6, 18 ].
was applied per dot. Different amounts of each synthetic peptide Thus, the phosphorylation of the MPM-2 site may serve was added to 3 ml of the MPM-2 antibody diluted to 1:20,000 and preincubated for 1 h prior to application to the dot-blot.
to regulate the functions of the various MPM-2 reactive
